| 臺大學術典藏 |
2021-07-03T03:33:57Z |
Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: Results of a randomized phase III trial
|
Cainap C.; Qin S.; Huang W.-T.; Chung I.J.; Pan H.; Cheng Y.; Kudo M.; Kang Y.-K.; PEI-JER CHEN; Toh H.-C.; Gorbunova V.; Eskens F.A.L.M.; Qian J.; McKee M.D.; Ricker J.L.; Carlson D.M.; El-Nowiem S. |
| 臺大學術典藏 |
2021-07-03T03:33:47Z |
Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update
|
Omata M.; Cheng A.-L.; Kokudo N.; Kudo M.; Lee J.M.; Jia J.; Tateishi R.; Han K.-H.; Chawla Y.K.; Shiina S.; Jafri W.; Payawal D.A.; Ohki T.; Ogasawara S.; PEI-JER CHEN; Lesmana C.R.A.; Lesmana L.A.; Gani R.A.; Obi S.; Dokmeci A.K.; Sarin S.K. |
| 臺大學術典藏 |
2021-02-19T06:52:26Z |
Efficacy and Safety of Ramucirumab in Asian and Non-Asian Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Individual Data Analysis of Two Randomized Studies
|
Yen C.-J.;Kudo M.;Lim H.-Y.;Chih-Hung Hsu;Vogel A.;Brandi G.;Cheng R.;Nitu I.S.;Abada P.;Hsu Y.;Zhu A.X.;Kang Y.-K.; Yen C.-J.; Kudo M.; Lim H.-Y.; CHIH-HUNG HSU; Vogel A.; Brandi G.; Cheng R.; Nitu I.S.; Abada P.; Hsu Y.; Zhu A.X.; Kang Y.-K. |
| 臺大學術典藏 |
2021-02-19T06:52:25Z |
Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab
|
Zhu A.X.;Finn R.S.;Kang Y.-K.;Yen C.-J.;Galle P.R.;Llovet J.M.;Assenat E.;Brandi G.;Motomura K.;Ohno I.;Daniele B.;Vogel A.;Yamashita T.;Chih-Hung Hsu;Gerken G.;Bilbruck J.;Hsu Y.;Liang K.;Widau R.C.;Wang C.;Abada P.;Kudo M.; Zhu A.X.; Finn R.S.; Kang Y.-K.; Yen C.-J.; Galle P.R.; Llovet J.M.; Assenat E.; Brandi G.; Motomura K.; Ohno I.; Daniele B.; Vogel A.; Yamashita T.; CHIH-HUNG HSU; Gerken G.; Bilbruck J.; Hsu Y.; Liang K.; Widau R.C.; Wang C.; Abada P.; Kudo M. |
| 臺大學術典藏 |
2021-02-18T08:01:12Z |
The afsumb consensus statements and recommendations for the clinical practice of contrast-enhanced ultrasound using sonazoid
|
Lee J.Y.; Minami Y.; Choi B.I.; Lee W.J.; Chou Y.-H.; Jeong W.K.; Park M.-S.; Kudo N.; Lee M.W.; Kamata K.; Iijima H.; Kim S.Y.; Numata K.; Sugimoto K.; Maruyama H.; Sumino Y.; Ogawa C.; Kitano M.; Joo I.; Arita J.; JA-DER LIANG; Lin H.-M.; Nolsoe C.; Gilja O.H.; Kudo M. |
| 臺大學術典藏 |
2021-02-18T08:01:11Z |
The AFSUMB consensus statements and recommendations for the clinical practice of contrast-enhanced ultrasound using sonazoid
|
Lee J.Y.; Minami Y.; Choi B.I.; Lee W.J.; Chou Y.-H.; Jeong W.K.; Park M.-S.; Kudo N.; Lee M.W.; Kamata K.; Iijima H.; Kim S.Y.; Numata K.; Sugimoto K.; Maruyama H.; Sumino Y.; Ogawa C.; Kitano M.; Joo I.; Arita J.; JA-DER LIANG; Lin H.-M.; Nolsoe C.; Gilja O.H.; Kudo M. |
| 臺大學術典藏 |
2021-02-18T02:09:13Z |
Corrigendum to Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis
|
Yau T.;Chiun Hsu;Kim T.-Y.;Choo S.-P.;Kang Y.-K.;Hou M.-M.;Numata K.;Yeo W.;Chopra A.;Ikeda M.;Kuromatsu R.;Moriguchi M.;Chao Y.;Zhao H.;Anderson J.;Dela Cruz C.;Kudo M.; Yau T.; Chiun Hsu; Kim T.-Y.; Choo S.-P.; Kang Y.-K.; Hou M.-M.; Numata K.; Yeo W.; Chopra A.; Ikeda M.; Kuromatsu R.; Moriguchi M.; Chao Y.; Zhao H.; Anderson J.; Dela Cruz C.; Kudo M. |
| 臺大學術典藏 |
2021-02-18T02:09:12Z |
Efficacy and Safety of Nivolumab plus Ipilimumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib: The CheckMate 040 Randomized Clinical Trial
|
Yau T.;Kang Y.-K.;Kim T.-Y.;El-Khoueiry A.B.;Santoro A.;Sangro B.;Melero I.;Kudo M.;Hou M.-M.;Matilla A.;Tovoli F.;Knox J.J.;Ruth He A.;El-Rayes B.F.;Acosta-Rivera M.;Lim H.-Y.;Neely J.;Shen Y.;Wisniewski T.;Anderson J.;Chiun Hsu; Yau T.; Kang Y.-K.; Kim T.-Y.; El-Khoueiry A.B.; Santoro A.; Sangro B.; Melero I.; Kudo M.; Hou M.-M.; Matilla A.; Tovoli F.; Knox J.J.; Ruth He A.; El-Rayes B.F.; Acosta-Rivera M.; Lim H.-Y.; Neely J.; Shen Y.; Wisniewski T.; Anderson J.; Chiun Hsu |
| 臺大學術典藏 |
2021-02-18T02:09:11Z |
Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma
|
Cheng A.-L.;Chiun Hsu;Chan S.L.;Choo S.-P.;Kudo M.; Cheng A.-L.; Chiun Hsu; Chan S.L.; Choo S.-P.; Kudo M. |
| 國立成功大學 |
2021 |
Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2
|
Kudo, M.;Galle, P.R.;Brandi, G.;Kang, Y.-K.;Yen, C.-J.;Finn, R.S.;Llovet, J.M.;Assenat, E.;Merle, P.;Chan, S.L.;Palmer, D.H.;Ikeda, M.;Yamashita, T.;Vogel, A.;Huang, Y.-H.;Abada, P.B.;Yoshikawa, R.;Shinozaki, K.;Wang, C.;Widau, R.C.;Zhu, A.X. |
